Status:
UNKNOWN
CysLT1-r Expression Following Allergen Exposure in Asthma and Allergic Rhinitis
Lead Sponsor:
Laval University
Conditions:
Asthma
Allergic Rhinitis
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
Cysteinyl leukotrienes (CysLTs) play an important role in asthma. CysLTs exert most of their bronchoconstrictive and pro-inflammatory effects through activation of the CysLT1-r. As allergic rhinitis a...
Detailed Description
We will recruit mild allergic asthmatic subjects and non asthmatic subjects with allergic rhinitis. On a baseline visit, allergy skin prick tests, spirometry, methacholine bronchoprovocation and induc...
Eligibility Criteria
Inclusion
- To have a positive reaction to one or more allergen on prick tests.
- Non smokers
- No respiratory track infection for at least one month prior to the study.
- Asthmatic subjects using only inhaled beta-2 agonists on an as needed basis for their asthma treatment.
- Asthmatic subjects with a history of asthma of at least 6 months.
- Asthmatic subjects with PC20 methacholine lower or equal to 8 mg/ml.
- Allergic rhinitic subjects never experienced any asthma symptoms or took any asthma medication in the past.
- Allergic rhinitic subjects with a PC20 methacholine higher than 16 mg/ml.
Exclusion
- Smokers or ex smokers less than 6 months or more than 10 pack-years.
- Asthmatic subjects using or used in the past 3 months inhaled or oral corticosteroids.
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00631254
Start Date
October 1 2003
End Date
January 1 2009
Last Update
May 12 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de recherche de l'Hopital Laval
Québec, Quebec, Canada, G1V 4G5